Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas
Status:
Recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
This is a phase 2, prospective, two-arm, randomized, open-label clinical trial determining
the efficacy of adjuvant trifluridine and tipiracil (TAS-102) in combination with irinotecan
in patients with ctDNA positive colon adenocarcinoma.